1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Yao, S.
Norton, R.S.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C5 H9 N O3
131.130
n
N-ACETYLALANINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
H2 N
16.023
AMINO GROUP
non-polymer
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
US
J.Med.Chem.
JMCMAR
0151
0022-2623
45
2310
2318
10.1021/jm010543z
12014969
Stabilization of the helical structure of Y2-selective analogues of neuropeptide Y by lactam bridges.
2002
To be Published
0353
Helical structure and self-association in a 13-residue neuropeptide Y Y2 receptor agonist: relationship to biological activity
NE
J.Biomol.NMR
JBNME9
0800
0925-2738
8
379
390
Solution structure of human neuropeptide Y
1996
10.2210/pdb1d0w/pdb
pdb_00001d0w
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
SYNTHETIC WITH MUTATION: L24A, I28K, I31L, T32E, A LACTAM-BRIDGE WAS INTRODUCED BETWEEN POSITIONS (28) AND (32)
1792.054
C-TERMINAL ANALOGUE OF NEUROPEPTIDE Y, A POTENT Y2 RECEPTOR AGONIST
C-TERMINAL ANALOGUE
L24A, I28K, I31L, T32E, A LACTAM-BRIDGE WAS INTRODUCED BETWEEN POSITIONS (28) AND (32)
1
syn
polymer
no
yes
(AYA)RHYKNLLERQRY(NH2)
ARHYKNLLERQRYX
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_nmr_exptl_sample_conditions
pdbx_struct_assembly
pdbx_struct_oper_list
struct_conn
struct_site
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Experimental preparation
1
0
2000-06-16
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_exptl_sample_conditions.pressure_units
_struct_conn.details
_struct_conn.pdbx_dist_value
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.ptnr1_auth_comp_id
_struct_conn.ptnr1_auth_seq_id
_struct_conn.ptnr1_label_atom_id
_struct_conn.ptnr1_label_comp_id
_struct_conn.ptnr1_label_seq_id
_struct_conn.ptnr2_auth_comp_id
_struct_conn.ptnr2_auth_seq_id
_struct_conn.ptnr2_label_atom_id
_struct_conn.ptnr2_label_comp_id
_struct_conn.ptnr2_label_seq_id
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
RCSB
Y
RCSB
1999-09-14
REL
REL
Chemically synthesized.
sample
THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES.
structures with the lowest energy
100
20
2D TOCSY
2D NOESY
DQF-COSY
5.0
1
atm
308
K
THE STRUCTURE WAS CALCULATED USING A TOTAL OF 124 UPPER BOUND DISTANCE RESTRAINTS AND 8 BACKBONE DIHEDRAL ANGLE CONSTRAINTS
simulated annealing
1
closest to the average
3.5 MG IN 0.6 ML H2O CONTAINING 30% TFE-D3 (BY VOLUME)
BRUKER
collection
XEASY
2.1
BARTELS
data analysis
XEASY
1.3
BRUNGER
structure solution
X-PLOR
3.85
BRUNGER
refinement
X-PLOR
3.85
600
Bruker
DRX
500
Bruker
AMX
ALA
24
n
1
AYA
24
A
ARG
25
n
2
ARG
25
A
HIS
26
n
3
HIS
26
A
TYR
27
n
4
TYR
27
A
LYS
28
n
5
LYS
28
A
ASN
29
n
6
ASN
29
A
LEU
30
n
7
LEU
30
A
LEU
31
n
8
LEU
31
A
GLU
32
n
9
GLU
32
A
ARG
33
n
10
ARG
33
A
GLN
34
n
11
GLN
34
A
ARG
35
n
12
ARG
35
A
TYR
36
n
13
TYR
36
A
NH2
37
n
14
NH2
37
A
author_defined_assembly
1
monomeric
A
AYA
24
N-ACETYLALANINE
A
AYA
1
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
4
-3.20
0.50
120.30
117.10
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
33
33
33
N
9
-3.29
0.50
120.30
117.01
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
33
33
33
N
12
-3.04
0.50
120.30
117.26
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
25
25
25
N
19
-3.62
0.50
120.30
116.68
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
33
33
33
N
20
-3.88
0.60
121.00
117.12
A
A
A
CB
CG
CD2
TYR
TYR
TYR
36
36
36
N
20
3.71
0.60
121.00
124.71
A
A
A
CB
CG
CD1
TYR
TYR
TYR
36
36
36
N
1
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
3
A
A
NE2
CD2
HIS
HIS
26
26
-0.067
0.011
1.373
1.306
N
4
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
5
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
6
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
7
A
A
NE2
CD2
HIS
HIS
26
26
-0.067
0.011
1.373
1.306
N
8
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
9
A
A
NE2
CD2
HIS
HIS
26
26
-0.067
0.011
1.373
1.306
N
11
A
A
NE2
CD2
HIS
HIS
26
26
-0.069
0.011
1.373
1.304
N
12
A
A
NE2
CD2
HIS
HIS
26
26
-0.067
0.011
1.373
1.306
N
13
A
A
NE2
CD2
HIS
HIS
26
26
-0.067
0.011
1.373
1.306
N
14
A
A
NE2
CD2
HIS
HIS
26
26
-0.068
0.011
1.373
1.305
N
15
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
18
A
A
NE2
CD2
HIS
HIS
26
26
-0.067
0.011
1.373
1.306
N
19
A
A
NE2
CD2
HIS
HIS
26
26
-0.066
0.011
1.373
1.307
N
20
A
A
NE2
CD2
HIS
HIS
26
26
-0.068
0.011
1.373
1.305
N
1
A
HIS
26
-107.86
47.52
1
A
TYR
27
-135.39
-65.02
2
A
HIS
26
-117.68
63.84
2
A
LEU
30
-102.47
-62.84
2
A
GLN
34
-35.96
-36.80
2
A
ARG
35
-101.93
51.85
3
A
TYR
27
-132.94
-60.24
3
A
LEU
30
-100.93
-61.19
3
A
GLN
34
-87.94
33.89
4
A
HIS
26
-108.23
41.14
4
A
LEU
30
-102.93
-67.00
5
A
ARG
25
-22.05
-49.44
5
A
TYR
27
-100.54
-67.36
5
A
ASN
29
-47.04
-11.22
5
A
LEU
30
-101.00
-62.70
5
A
GLU
32
-99.92
34.24
5
A
GLN
34
-24.38
-53.02
6
A
ARG
25
-101.20
-62.48
6
A
HIS
26
-109.15
68.52
6
A
TYR
27
-110.46
-74.80
7
A
TYR
27
-125.93
-66.16
7
A
LEU
30
-101.01
-60.03
7
A
GLN
34
-25.20
-71.55
8
A
ARG
25
-111.68
-79.55
8
A
HIS
26
-91.99
55.40
8
A
ASN
29
-47.27
13.55
8
A
GLU
32
-97.12
30.79
9
A
HIS
26
-3.18
64.65
9
A
TYR
27
-127.98
-59.75
9
A
ASN
29
-36.76
-37.96
9
A
ARG
35
-95.24
50.01
10
A
ARG
25
-98.12
-67.31
10
A
ASN
29
-46.50
11.14
10
A
GLN
34
-100.81
-68.15
11
A
TYR
27
-17.07
-59.00
12
A
ARG
25
-23.94
-53.68
12
A
TYR
27
-123.47
-62.93
12
A
ASN
29
-65.92
25.48
12
A
LEU
30
-101.12
-60.35
12
A
ARG
35
-109.09
41.45
13
A
ARG
25
15.13
-57.61
13
A
TYR
27
-105.96
-63.38
13
A
ASN
29
-62.16
14.67
13
A
ARG
33
-100.77
-61.37
13
A
GLN
34
-19.34
-55.20
13
A
ARG
35
-148.76
43.14
14
A
HIS
26
-93.84
40.74
14
A
ASN
29
-47.85
-14.96
14
A
GLN
34
-20.06
-34.95
15
A
ASN
29
-64.16
0.18
15
A
GLN
34
-19.58
-61.89
15
A
ARG
35
171.98
44.20
16
A
ARG
25
-15.62
-54.95
16
A
TYR
27
-125.37
-58.59
16
A
ASN
29
-57.96
-8.58
16
A
LEU
30
-102.38
-61.13
16
A
ARG
35
-115.18
56.75
17
A
ARG
25
-124.77
-50.01
17
A
HIS
26
-107.43
78.85
17
A
TYR
27
-145.79
-64.13
17
A
ASN
29
-47.91
-3.50
17
A
GLU
32
-91.11
32.09
17
A
ARG
33
-102.87
-65.70
17
A
GLN
34
-18.75
-63.89
17
A
ARG
35
-145.12
51.37
18
A
ARG
25
-105.62
-75.71
18
A
GLN
34
-19.92
-66.24
19
A
ARG
25
-120.31
-55.97
19
A
TYR
27
-141.87
-75.52
19
A
ASN
29
-59.21
10.19
19
A
ARG
33
-100.02
-67.78
20
A
ARG
25
-130.17
-63.42
20
A
ASN
29
-69.94
2.91
20
A
LEU
30
-102.62
-63.16
20
A
GLN
34
-20.70
-64.94
20
A
ARG
35
-140.71
44.99
SOLUTION STRUCTURE OF LACTAM-BRIDGED C-TERMINAL ANALOGUE-I OF NEUROPEPTIDE Y
1
N
N
A
TYR
27
A
TYR
4
HELX_P
A
GLU
32
A
GLU
9
1
1
6
covale
1.311
both
A
AYA
24
A
C
AYA
1
1_555
A
ARG
25
A
N
ARG
2
1_555
covale
LACTAM-BRIDGE WAS INTRODUCED
1.311
none
A
LYS
28
A
NZ
LYS
5
1_555
A
GLU
32
A
CD
GLU
9
1_555
covale
1.298
both
A
TYR
36
A
C
TYR
13
1_555
A
NH2
37
A
N
NH2
14
1_555
NEUROPEPTIDE
LACTAM-BRIDGED, HELIX, NEUROPEPTIDE
1D0W
PDB
1
1D0W
24
37
1D0W
24
37
1D0W
A
1
1
14
BINDING SITE FOR RESIDUE NH2 A 37
A
NH2
37
Software
2
A
ARG
35
A
ARG
12
2
1_555
A
TYR
36
A
TYR
13
2
1_555
1
P 1